From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data
ATC code
  • None
CAS Number
PubChem CID
Chemical and physical data
Formula C22H17F2N5OS
Molar mass 437.465086 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Ravuconazole (codenamed BMS-207147 and ER-30346) is a potent triazole antifungal, being developed by Bristol-Myers Squibb, that is currently in phase I/II clinical trials.[1] The drug has shown to have a similar spectrum of activity to voriconazole, with an increased half-life.[2] However, ravuconazole has limited activity against species of Fusarium, Scedosporium, and Zygomycetes.[3][4]

See also[edit]


  1. ^ National Cancer Institute. Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2010 Feb 18]. Available from: http://clinicaltrials.gov/ct2/show/NCT00064311?term=ravuconazole&spons_ex=Y&rank=1 NLM Identifier: NCT00064311.
  2. ^ The Aspergillus Website, Pasqualotto AC, Denning DW. Ravuconazole. Date accessed: 2010 Feb 18.
  3. ^ Pasqualotto AC, Thiele KO, Goldani LZ (2010). "Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole". Curr Opin Investig Drugs. 11 (2): 165–74. PMID 20112166. 
  4. ^ Pfaller, M. A.; Messer, S. A.; Hollis, R. J.; Jones, R. N.; Sentry Participants, Group (2002). "Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000". Antimicrobial Agents and Chemotherapy. 46 (4): 1032–7. doi:10.1128/AAC.46.4.1032-1037.2002. PMC 127116Freely accessible. PMID 11897586.